Urogen Pharma Ltd. (URGN) is now a commercial biotechnology company that designs and develops therapies for urological pathologies. It was founded in 2004, and while technically incorporated in Israel, URGN's corporate offices are located in Princeton, New Jersey. The company had 173 employees as of 2/17/2020, of which 127 were in the United States and 46 work out of Israel.
URGN's primary technology is called RTGel, which is a drug delivery system. RTGel allows a medicine (URGN's two flagship products use mitimycin) to be delivered in a liquid form that then turns into